Certolizumab pegol
Top View
- Human Igg1 Antibody
- INN Working Document 05.179 Update 2011
- Administrative
- International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
- (INN) for Biological and Biotechnological Substances
- Benlysta® (Belimumab) - Effective May 1, 2018
- Certolizumab Pegol in the Treatment of Crohn's Disease
- Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- CIMZIA (Certolizumab Pegol) for Injection, for Subcutaneous Use CIMZIA (Certolizumab Pegol) Injection, for Subcutaneous Use ------CONTRAINDICATIONS------ Initial U.S
- (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
- Crohn's Disease – Infliximab (Review), Certolizumab Pegol and Natalizumab
- Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: an Overview
- Certolizumab Pegol Treatment in Three Patients with Takayasu Arteritis
- Certolizumab Pegol)
- Medical Policy Update Bulletin: August 2021
- Crohn's Disease – Infliximab
- Customs Tariff - Schedule Xxi - 1